Skip to content

A study evaluating the effect of notification of postprandial hyperglycemia and supporting counter measures on the habits of eating and exercising, and on the parameters of glucose metabolism.

A study evaluating the effect of notification of postprandial hyperglycemia and supporting counter measures on the habits of eating and exercising, and on the parameters of glucose metabolism. - A study evaluating the effect of notification of postprandial hyperglycemia and supporting counter measures on the habits of eating and exercising, and on the parameters of glucose metabolism.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049114
Enrollment
75
Registered
2022-10-06
Start date
2022-10-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Subjects follow the instructions of life-style work as counter measures, while they record their daily implementation for 3-4 months. Subjects take notification of possible postprandial hyperglycemia.

Sponsors

Suntory Global Innovation Center Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Healthy male and female subjects whose ages are 20 <= years old <65. (2)Subjects who agree with the given description and express informed consent via Web or written documents. (3)Subjects who underwent an annual medical check-up in 2022. (4)Subjects whose fasting blood glucose (FPG) is equal to or more than 100 mg/dL, and whose FPG is lower than 126 mg/dL. (5)Subjects whose predicted blood glucose level during the 75g OGTT is equivalent to or more than 126 mg/dL at 120 min., or whose predicted Matsuda-index is lower than 4.97, based on the algorithm calculation. (6)Subjects who can use the smartphone application.

Exclusion criteria

Exclusion criteria: (1)Systolic pressure <90 mmHg (2)Pregnant or lactating. (3)Who donated over 200ml blood components or whole blood within the past 4 weeks prior to the current study. (4)Male who donated over 400ml whole blood within the past 12 weeks prior to the current study. (5)Female who donated over 400ml whole blood within the past 16 weeks prior to the current study. (6)Male whose blood was collected more than 1200 mL within the last twelve months when the amount of blood sampling in the current study is added. (7)Female whose blood was collected more than 800 mL within the last twelve months when the amount of blood sampling in the current study is added. (8)Who are participating in other clinical studies, or who finished clinical study within the last 4 weeks. (9)Subjects a)with disease on heart, liver, kidney or other organs complications. b)with a previous history of disease on circulatory organs. c)who are contracting diabetes. (10)Who have possibility to be diagnosed as diabetes; whose HbA1c is equal to or more than 6.5 % or have past medical history of diabetes. (11)Who have increased the frequency of hard physical activity 1 day or more after a medical check-up conducted in 2022, or who have those constant habits 3 days or more per week. (12)Who restrict diets including carbohydrate. (13)Who must follow the specific health guidance. (14)With a previous history of feeling sick after blood sampling. (15)Who have difficulty in blood sampling from peripheral vein. (16)Who drink alcohol a lot. (17)Who have irregular eating patterns. (18)Who work irregular shifts or at midnight. (19)Whose BMI is less than 18.5 or equal to or more than 30.0 kg/m2. (20)Who are contracting alcohol hypersensitivity. (21)Who are judged as unsuitable for the study by the principal investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
HbA1c

Countries

Japan

Contacts

Public ContactShinya Fukizawa

Suntory Global Innovation Center Ltd. Research Institute

Shinya_Fukizawa@suntory.co.jp050-3182-0595

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026